379 related articles for article (PubMed ID: 28061466)
1. Prostate cancer proteomics: Current trends and future perspectives for biomarker discovery.
Tanase CP; Codrici E; Popescu ID; Mihai S; Enciu AM; Necula LG; Preda A; Ismail G; Albulescu R
Oncotarget; 2017 Mar; 8(11):18497-18512. PubMed ID: 28061466
[TBL] [Abstract][Full Text] [Related]
2. Urinary biomarkers in prostate cancer detection and monitoring progression.
Wu D; Ni J; Beretov J; Cozzi P; Willcox M; Wasinger V; Walsh B; Graham P; Li Y
Crit Rev Oncol Hematol; 2017 Oct; 118():15-26. PubMed ID: 28917266
[TBL] [Abstract][Full Text] [Related]
3. MALDI mass spectrometry in prostate cancer biomarker discovery.
Flatley B; Malone P; Cramer R
Biochim Biophys Acta; 2014 May; 1844(5):940-9. PubMed ID: 23831156
[TBL] [Abstract][Full Text] [Related]
4. Proteomics in diagnosis of prostate cancer.
Davalieva K; Polenakovic M
Pril (Makedon Akad Nauk Umet Odd Med Nauki); 2015; 36(1):5-36. PubMed ID: 26076772
[TBL] [Abstract][Full Text] [Related]
5. SELDI protein profiling of dunning R-3327 derived cell lines: identification of molecular markers of prostate cancer progression.
Malik G; Rojahn E; Ward MD; Gretzer MB; Partin AW; Semmes OJ; Veltri RW
Prostate; 2007 Oct; 67(14):1565-75. PubMed ID: 17705230
[TBL] [Abstract][Full Text] [Related]
6. Mass spectrometry-based expression profiling of clinical prostate cancer.
Wright ME; Han DK; Aebersold R
Mol Cell Proteomics; 2005 Apr; 4(4):545-54. PubMed ID: 15695425
[TBL] [Abstract][Full Text] [Related]
7. Identification of clinically relevant protein targets in prostate cancer with 2D-DIGE coupled mass spectrometry and systems biology network platform.
Ummanni R; Mundt F; Pospisil H; Venz S; Scharf C; Barett C; Fälth M; Köllermann J; Walther R; Schlomm T; Sauter G; Bokemeyer C; Sültmann H; Schuppert A; Brümmendorf TH; Balabanov S
PLoS One; 2011 Feb; 6(2):e16833. PubMed ID: 21347291
[TBL] [Abstract][Full Text] [Related]
8. New technologies for biomarker analysis of prostate cancer progression: Laser capture microdissection and tissue proteomics.
Paweletz CP; Liotta LA; Petricoin EF
Urology; 2001 Apr; 57(4 Suppl 1):160-3. PubMed ID: 11295617
[TBL] [Abstract][Full Text] [Related]
9. Discovery of serum protein biomarkers for prostate cancer progression by proteomic analysis.
Al-Ruwaili JA; Larkin SE; Zeidan BA; Taylor MG; Adra CN; Aukim-Hastie CL; Townsend PA
Cancer Genomics Proteomics; 2010; 7(2):93-103. PubMed ID: 20335524
[TBL] [Abstract][Full Text] [Related]
10. A data-analytic strategy for protein biomarker discovery: profiling of high-dimensional proteomic data for cancer detection.
Yasui Y; Pepe M; Thompson ML; Adam BL; Wright GL; Qu Y; Potter JD; Winget M; Thornquist M; Feng Z
Biostatistics; 2003 Jul; 4(3):449-63. PubMed ID: 12925511
[TBL] [Abstract][Full Text] [Related]
11. The Proteome of Primary Prostate Cancer.
Iglesias-Gato D; Wikström P; Tyanova S; Lavallee C; Thysell E; Carlsson J; Hägglöf C; Cox J; Andrén O; Stattin P; Egevad L; Widmark A; Bjartell A; Collins CC; Bergh A; Geiger T; Mann M; Flores-Morales A
Eur Urol; 2016 May; 69(5):942-52. PubMed ID: 26651926
[TBL] [Abstract][Full Text] [Related]
12. Proteomic analysis of prostate cancer metastasis-derived prostasomes.
Ronquist KG; Ronquist G; Larsson A; Carlsson L
Anticancer Res; 2010 Feb; 30(2):285-90. PubMed ID: 20332430
[TBL] [Abstract][Full Text] [Related]
13. Differential profiling of prostate tumors versus benign prostatic tissues by using a 2DE-MALDI-TOF-based proteomic approach.
Kmeťová Sivoňová M; Tatarková Z; Jurečeková J; Kliment J; Híveš M; Lichardusová L; Kaplán P
Neoplasma; 2021 Jan; 68(1):154-164. PubMed ID: 32977723
[TBL] [Abstract][Full Text] [Related]
14. Proteomic profiling of exosomes leads to the identification of novel biomarkers for prostate cancer.
Duijvesz D; Burnum-Johnson KE; Gritsenko MA; Hoogland AM; Vredenbregt-van den Berg MS; Willemsen R; Luider T; Paša-Tolić L; Jenster G
PLoS One; 2013; 8(12):e82589. PubMed ID: 24391718
[TBL] [Abstract][Full Text] [Related]
15. Urine TMPRSS2:ERG fusion transcript integrated with PCA3 score, genotyping, and biological features are correlated to the results of prostatic biopsies in men at risk of prostate cancer.
Cornu JN; Cancel-Tassin G; Egrot C; Gaffory C; Haab F; Cussenot O
Prostate; 2013 Feb; 73(3):242-9. PubMed ID: 22821767
[TBL] [Abstract][Full Text] [Related]
16. Prohibitin identified by proteomic analysis of prostate biopsies distinguishes hyperplasia and cancer.
Ummanni R; Junker H; Zimmermann U; Venz S; Teller S; Giebel J; Scharf C; Woenckhaus C; Dombrowski F; Walther R
Cancer Lett; 2008 Aug; 266(2):171-85. PubMed ID: 18384941
[TBL] [Abstract][Full Text] [Related]
17. [Proteomic analysis of prostate cancer using surface enhanced laser desorption/ionization mass spectrometry].
Pan YZ; Xiao XY; Zhao D; Zhang L; Ji GY; Li Y; He DC; Zhao XJ; Yang BX
Zhonghua Yi Xue Za Zhi; 2005 Nov; 85(45):3172-5. PubMed ID: 16405834
[TBL] [Abstract][Full Text] [Related]
18. Altered PCA3 and TMPRSS2-ERG expression in histologically benign regions of cancerous prostates: a systematic, quantitative mRNA analysis in five prostates.
Väänänen RM; Ochoa NT; Boström PJ; Taimen P; Pettersson K
BMC Urol; 2015 Aug; 15():88. PubMed ID: 26294063
[TBL] [Abstract][Full Text] [Related]
19. A serum proteomic pattern for the detection of colorectal adenocarcinoma using surface enhanced laser desorption and ionization mass spectrometry.
Liu XP; Shen J; Li ZF; Yan L; Gu J
Cancer Invest; 2006 Dec; 24(8):747-53. PubMed ID: 17162557
[TBL] [Abstract][Full Text] [Related]
20. The use of matrix coating assisted by an electric field (MCAEF) to enhance mass spectrometric imaging of human prostate cancer biomarkers.
Wang X; Han J; Hardie DB; Yang J; Borchers CH
J Mass Spectrom; 2016 Jan; 51(1):86-95. PubMed ID: 26757076
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]